This project is a 2-phase, randomized clinical trial that includes 7 days of unilateral leg disuse (Phase 1), immediately followed by 1 week of bilateral leg rehabilitation (Phase 2). The investigators will recruit cohorts of healthy middle-aged men and women to address their aims: * Demonstrate the sex-specific effects of skeletal muscle disuse (Phase 1) * Identify key molecular determinates of susceptibility of skeletal muscle atrophy (Phase 1) * Map the early, sex-specific molecular time-course of rehabilitation (Phase 2) * Determine if disused and healthy muscle respond similarly to exercise (Phase 2) Healthy, middle-age men and post-menopausal women (50-65 years) will be recruited from the greater Houston/Galveston area. This under-represented research demographic demonstrate few negative metabolic or phenotypic signs of advanced age, but are at increased risk of being hospitalized and experiencing accelerated loss of lean mass and muscle function that parallels a much older population. The goal of this study is to characterize phenotypic and molecular skeletal muscle changes in middle-aged men and women during critical periods of disuse and rehabilitation and ultimately direct the development of targeted and effective prevention and treatment strategies.
Age range
50 Years – 65 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Quantitative RNA-sequencing
Timeframe: Study day 1 (before starting leg disuse)
Quantitative RNA-sequencing
Timeframe: Study day 7 (after finishing leg disuse)
Quantitative RNA-sequencing
Timeframe: Study day 7 (after 1 bout of rehabilitation)
Quantitative RNA-sequencing
Timeframe: Study day 9 (after 2 bouts of rehabilitation)
Quantitative RNA-sequencing
Timeframe: Study Day 11 (after 3 bouts of rehabilitation)
Quantitative RNA-sequencing
Timeframe: Study Day 21 (after finishing 7 bouts of rehabilitation)
Muscle function
Timeframe: Study day 1 (before starting leg disuse)
Muscle function
Timeframe: Study day 7 (after 1 bout of rehabilitation)
Muscle function
Timeframe: Study day 9 (after 2 bouts of rehabilitation)
Muscle function
Timeframe: Study Day 11 (after 3 bouts of rehabilitation)
Muscle function
Timeframe: Study Day 21 (after finishing 7 bouts of rehabilitation)
Body (leg) composition
Timeframe: Study day 1 (before starting leg disuse)
Body (leg) composition
Timeframe: Study day 7 (after finishing leg disuse)
Body (leg) composition
Timeframe: Study day 9 (after 2 bouts of rehabilitation)
Body (leg) composition
Timeframe: Study Day 11 (after 3 bouts of rehabilitation)
Body (leg) composition
Timeframe: Study Day 21 (after finishing 7 bouts of rehabilitation)